ClinVar

Description

A variant of uncertain significance has been identified in the FBN1 gene. The G585R variant, arising from the c.1753 G>A nucleotide substitution, has not been published as pathogenic or been reported as benign to our knowledge. This variant is also not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The G585R variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. Furthermore, this substitution occurs at a position that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. The same G585R missense variant arising from a different nucleotide substitution in the FBN1 gene, c.1753 G>C, has been reported in one individual diagnosed with incomplete Marfan syndrome who had a family history suggestive of Marfan syndrome (Khau Van Kien et al., 2010). Additionally, a different missense variant at the same residue in the FBN1 gene (G585E) has been reported in association with Marfan syndrome (Baumgartner et al., 2005). However, no segregation data were reported for either the c.1753 G>C (G585R) or G585E variants, and the clinical significance of these variants remain to be definitively determined. Moreover, G585R does not affect a Cysteine residue within a calcium-binding (cb) EGF-like domain of the FBN1 gene, which is the most common mechanism of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003).